Table 2. Characterization of patients with end-stage heart failure.
| Heart failure patients (n = 18) | |
|---|---|
| Age (years) | 48.9 ± 2.4 |
| Gender | n = 14 males, n = 4 females |
| NYHA class | n = 8 NYHA III, n = 10 NYHA IV |
| Pro-BNP (pmol/L) | 417.0 ± 85.0 |
| BMI (kg/m2) | 26.0 ± 0.7 |
| LVEF (%) | 19.2 ± 1.6 |
| LVEDV (ml) | 279.0 ± 23.2 |
| LVESV (ml) | 227.9 ± 21.7 |
| SV (ml) | 51.1 ± 3.6 |
| WMSI | 2.42 ± 0.04 |
| IVSd (cm) | 0.81 ± 0.05 |
| LVPWd (cm) | 0.71 ± 0.02 |
| LVIDd (cm) | 7.41 ± 0.22 |
Clinical and echocardiography data (mean±SEM) of patients with end-stage heart failure with reduced ejection fraction (HFrEF). Non-diseased hearts considered for transplantation but deemed unsuitable were used as control samples (age 46.9 ± 7.5 years, n = 4 males and n = 3 females). NYHA, New York Heart Association; BMI, body mass index; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; WMSI, wall motion score index [8]; LVEDV, LV end diastolic volume; LVESV, LV end systolic volume; SV, stroke volume; IVSd, interventricular septal diameter in diastole; LVIDd, LV internal diameter in diastole; LVPWd, LV posterior wall thickness in diastole.